Home
SHC 2024
S’pore MASLD Symposium
Science of HBV Cure
Preceptorship Prog.
Abstracts/Posters
Info
e-Resources
Contact

My Account
- Login

Home
SHC 2024
S’pore MASLD Symposium
Science of HBV Cure
Preceptorship Prog.
Abstracts/Posters
Info
e-Resources
Contact

Speaker Agreement

Speaker Faculty Agreement

Our Sponsors

List of Sponsor Coming Soon…

Our Partners

Malaysian Society of Gastroenterology and Hepatology (MSGH)

Indonesian Association for Study of Liver (Ina ASL)

Thai Association for Study of Liver (THASL)

Myanmar Gastroenterology and Liver Society (MGLS)

Gastroenterological Society of Singapore (GESS)

Our Hotel Partner

List of Hotel Partner Coming Soon…

Join our community

Important links

American Association for Study of Liver Disease (AASLD)

European Association for Study of Liver (EASL)

Asia Pacific Association for Study of Liver (APASL)

International Liver Cancer Association (ILCA)

© 2024 Singapore Hepatitis Conference Pte Ltd | All Rights Reserved

Dr. Ken Liu

Dr. Ken Liu (MBBS, BSc, PhD, FRACP) is a clinician scientist and staff specialist transplant hepatologist at the Australian National Liver Transplant Unit, Royal Prince Alfred Hospital (RPAH). Prior to becoming a consultant, he spent a year overseas as the hepatology fellow at The Chinese University of Hong Kong conducting clinical and laboratory research. He has also completed a laboratory-based PhD investigating novel systemic treatments to target tumour vasculature and immune response in primary liver cancer using mouse liver injury models. This work was awarded an NHMRC postgraduate scholarship and the Peter Bancroft Prize for Research.

Prof. Heiner Wedemeyer

Professor Heiner Wedemeyer is a full professor and Head and Chair of the Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology at Hannover Medical School, Hannover, Germany. Professor Wedemeyer’s main interests are the immunopathogenesis of HBV, HCV, HDV, and HEV infections, as well as the development of novel immunomodulatory therapies, the hepatological treatment of acute and chronic liver diseases and the treatment of liver cancer that can lead to liver transplantation. He has been Principal Investigator on several Phase 1–4 clinical trials on antivirals and immunotherapies in viral hepatitis. Professor Wedemeyer has been involved in the scientific coordination of the German Network of Competence on Viral Hepatitis (Hep-Net) since 2002, and the German Liver Foundation since 2006.

Professor Wedemeyer has authored more than 530 original articles in international peer-reviewed journals, including several national and international guidelines on the management of HBV, HCV, HDV and hepatocellular carcinoma.

Dr. Harry Janssen

Dr. Harry Janssen is a Professor of the Department of Gastroenterology and Hepatology at Erasmus MC, Rotterdam, The Netherlands.

Dr. Janssen has led numerous international multicenter clinical and translational studies on the natural history and treatment for chronic viral hepatitis and other liver diseases. His clinical and translational research aiming for immunological control and cure of hepatitis B and C has led to several globally used novel treatment concepts. He is currently the most cited global expert in chronic hepatitis B (Expertscape nr 1 among 28.932 scientists). His research contributions include sustained federal funding (greater than 20 years), over 600 peer reviewed publications, an H-index of 115, and over 60,000 citations (Google Scholar). He has acquired over $50 million USD in research funding from many different organizations among which NIH, European Commission, CIHR, NWO and ZonMW.

Dr. Calvin Koh

Dr Koh Jianyi, Calvin obtained his medical degree (MBBS) from the National University of Singapore and underwent further medical training at the National University Hospital, Singapore, in the division of gastroenterology and hepatology, completing his Advanced Specialist Training in gastroenterology.

Following completion of specialist training, he was awarded an Academic Medicine Development Award and undertook an advanced endoscopy fellowship under the auspices of the American Society for Gastrointestinal Endoscopy with the Division of Gastroenterology, Hepatology and Nutrition at the University of Florida, USA to further his interest in interventional endoscopy.

Dr Koh is currently a Consultant at the Division of Gastroenterology and Hepatology, as well as an Assistant Professor at NUS Yong Loo Lin School of Medicine. He currently serves as the director of the Endoscopy Centre, at National University Hospital, Singapore, as well as a core faculty member for the gastroenterology training program. He is a fellow of the Royal College of Physicians (London), as well as the American Society of Gastrointestinal Endoscopy.

His clinical and research interests are pancreatobiliary disease, gastric cancer, colon cancer and general gastroenterology/hepatology. Besides gastroscopy and colonoscopy, he also performs endoscopic retrograde cholangiopancreatography, endoscopic ultrasound, endoscopic mucosal resection of polyps, small bowel enteroscopy.

Prof. Arun Sanyal

Prof. Arun Sanyal, M.D., is the interim Chair of the Department of Gastroenterology, Hepatology and Nutrition and Professor of Medicine, Physiology and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University (VCU) Medical Center in Richmond, Virginia. Prof. Sanyal has recently been named Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health. Prof. Sanyal also serves as Chairman of the NIH NASH Clinical Research Network, the NIMBLE consortium and the Liver Forum for NASH and fibrosis. His research interests include all aspects of NAFLD and NASH as well as complications of cirrhosis and end stage liver disease. He has been continuously funded by the NIH since 1995 and has over 350 peer reviewed publications with a H-index of 116. He was also recently ranked in top 0.01% of medical scientists based on their impact on the field (PlosBio 2019). He has served in several leadership roles nationally and globally including Chair of the Hepatobiliary Pathophysiology Study Section of the NIH, Secretary and then President of the American Association for Study of Liver Disease, founding member of the American Board of Internal Medicine Transplant Hepatology board examination and member of WHO advisory council on viral hepatitis. He is the co-founder and academic chair of the Liver Forum which is a platform to bring regulatory agencies (FDA and EMA) with industry and academics to accelerate drug development for NASH and advanced liver disease. He is currently engaged in numerous clinical trials and leads several phase 2B and 3 trials for NASH as well as complications of end stage liver disease. His contributions have been recognized by receiving the Distinguished Mentorship Award from the American Gastroenterological Association and the Distinguished Scientific Achievement Award from the American Liver Foundation in 2017 and the Distinguished Achievement Award from the AASLD in 2018.

Prof. Prof. Ed Gane

Prof. Ed Gane, MBCHB, MD, FRACP, FRSNZ, FAASLD, MNZM
New Zealand Liver Transplant Unit
Auckland City Hospital, New Zealand

Prof. Gane is Professor of Medicine at the University of Auckland, New Zealand, Hepatologist and Deputy Director of the New Zealand Liver Unit at Auckland City Hospital.
Prof. Gane trained in hepatology at the Institute of Liver Studies, King’s College School of Medicine, London, where he completed his MD on the pathogenesis of hepatitis C-related liver injury. Prof. Gane chairs the Ministry of Health committee responsible for HCV elimination and co-wrote the first New Zealand National HepC Action Plan.
Prof. Gane is an investigator for many international clinical trials with particular interest in early phase development of new direct acting antiviral therapies against chronic hepatitis C, hepatitis B, NASH and HCC. He has published over 600 papers in peer-reviewed journals including The Lancet and The New England Journal of Medicine. Prof. Gane is a member of APASL, EASL, ILTS, ILCA and AASLD and is an Associate Editor for the Journal of Hepatology
In 2011, Prof. Gane received the New Zealand Health Research Council (NZHRC) annual Beaven Medal and in 2014, the NZHRC annual Liley Medal.
In 2011, Prof. Gane was awarded Member of the Order of New Zealand for Services to Medicine.
In 2017, Prof. Gane was named as New Zealand Innovator of the Year for his work towards HCV elimination in New Zealand.
In 2018, he was elected to the Royal Society of Medicine.

Prof. Pierce Chow

Pierce Chow is Professor and Program Director at the Duke-NUS Medical School and Senior Consultant Surgeon at the National Cancer Centre Singapore (NCCS) and the Singapore General Hospital. He is concurrently a National Medical Research Council (NMRC) funded Senior Clinician-Scientist and was the founding President of the College of Clinician Scientists, Academy of Medicine Singapore. Prof Chow was conferred the Chapter of Surgeon’s Gold Medal in the conjoint FRCSE/MMed examination in 1995, and after completing his surgical residency and PhD, he trained in liver transplantation with Professor Russell Strong in Australia. Pierce leads the multi-disciplinary NMRC TCR National Flagship Program in Liver Cancer. In 2020, he was awarded an A*STAR IAF-ICP grant to conduct a nation-wide 2000-patient cohort study to develop diagnostics for early detection of hepatocellular carcinoma in high-risk patients. Pierce is also a faculty member at the Genome Institute of Singapore, the SingHealth Duke-NUS Global Health Institute and Research Director at the Institute of Cell and Molecular Biology Singapore. Prof Chow was conferred the NMRC National Outstanding Clinician Scientist Award in 2012 for improving clinical outcomes with his research on Liver Cancer.

Prof. Yock Young Dan

Prof. Yock Young Dan
MBBS (S’pore), Ph.D, MMed (Int Med), MRCP (UK), FAMS (Gastroenterology) Head, Dept. of Medicine, NUH
Head and A/ Professor, Dept. of Medicine, NUS Adjunct, Cancer Science Institute
Associate Faculty, GIS Partnership Programme, Genome Institute of Singapore
Senior Consultant, Div. of Gastroenterology & Hepatology, Dept. of Medicine, NUH
Senior Consultant, Liver Transplantation, National University Centre for Organ Transplantation, NUH
Dr Dan Yock Young obtained his basic medical degree (MBBS) from the National University of Singapore in 1994. He went on to complete his basic specialty training and obtained a Master of Internal Medicine (MMED S’pore) and membership of the Royal Colleges of Physicians of the UK, MRCP (UK) in 1998. He obtained his Gastroenterology fellowship from the Academy of Medicine, Singapore (FAMS S’pore) in 2003. From 2003 to 2005, Dr Dan was awarded the A*STAR International Fellowship and he spent 2 years at the University of Washington researching liver stem cells and liver regeneration. This work subsequently led to him being awarded a PhD from NUS in 2010.

He has vast clinical interests in hepatology which includes viral hepatitis B and C, liver transplantation and liver cirrhosis. He is a clinician scientist and his interests include the cost-effectiveness of clinical treatments, liver progenitor cells and their therapeutic applications, as well as pathogenesis and treatment targets in liver failure.

Dr. Thomas Tu

Dr. Thomas Tu is a molecular biologist with a particular focus on integrated Hepatitis B virus DNA and its role in disease progression. He currently leads a research group at the Westmead Institute for Medical Research in the Storr Liver Centre (Sydney, Australia), where his team focuses on persistent forms of the Hepatitis B virus (covalently closed circular DNA and integrated HBV DNA). He is particularly passionate about developing a HBV cure and mitigating the associated liver cancer, as he himself lives with chronic Hepatitis B.
Dr. Tu is currently President of the Australian Centre for Hepatitis Virology (ACHV), the premier Australian society for hepatitis virus researchers. He is also board member of Hepatitis Australia, guiding the strategic direction of the peak national advocacy body for people with liver disease. Finally, Dr. Tu is founder and Executive Director of HepBCommunity.org (a global support network for people affected with HBV), guiding people through their HBV diagnosis and linking them with trustworthy scientific and medical information.

Prof. Vincent Wong

MBChB (Hons), MD (CUHK), FRCP (Edin), FHKCP, FHKAM (Medicine)
Professor, Dept. of Medicine & Therapeutics Head, Div. of Gastroenterology and Hepatology
Director, Cheng Suen Man Shook Centre for Hepatitis Research Deputy Director, Center for Liver Health
Faculty of Medicine, The Chinese University of Hong Kong Honorary Consultant, Prince of Wales Hospital, Hospital Authority
Vincent Wong, MD, is a Professor in the Department of Medicine and Therapeutics at the Chinese University of Hong Kong, where he undertakes research on aspects of viral hepatitis and
non-alcoholic fatty liver disease (NAFLD). Along with authoring over 350 articles in international medical journals, Prof. Wong is a pioneer in the development of hepatocellular carcinoma prediction scores and has performed important validation studies on the non-invasive assessment of NAFLD by transient elastography.

Dr Dean Tai

Co-founder & Chief Scientific Officer (CSO)
As the CSO of HistoIndex, Dean is responsible for the strategic product development and worldwide research collaboration. Together with his HistoIndex co-founder, Dr. Gideon Ho, Dean has successfully launched the company’s platform technology in multiple global clinical studies. He has established multi-centre clinical trials with key opinion leaders, and successfully coordinated clinical validation worldwide using HistoIndex’s proprietary imaging and analysis technology .

George Goh

Dr. George Goh is a Senior Consultant Gastroenterologist and Hepatologist at the Singapore General Hospital. After Gastroenterology specialist training at Singapore General Hospital, he underwent further advanced subspecialty training in Hepatology at the Cleveland Clinic (USA), with a research focus on non-alcoholic fatty liver disease (NAFLD). He returned to establish a dedicated Metabolic Liver Clinic with multi-disciplinary involvement that helps to identify, prognosticate and manage patients with severe NAFLD. In addition, he remains actively involved in research and is the local Principal Investigator of several ongoing international NAFLD trials. He has published in the fields of NAFLD, liver cirrhosis, hepatocellular carcinoma and organ transplantation, and has been an invited faculty at both local and international conferences.
Dr Goh is an appointed Clinical Associate Professor at Duke-NUS Medical School and Clinical Lecturer at Yong Loo Lin School of Medicine, National University of Singapore. He is the current Chairman of the National Foundation of Digestive Disease (NFDD), which aims to increase awareness of such diseases among the general public.

Prof. Lim Seng Gee

Qualifications:
MBBS (Hons Monash), FRACP (Aust), FRCP (London), MD (Monash), FAMS (S’pore), Cert Immunology (King’s College)

Biosketch
Prof Lim currently serves as a Senior Consultant at the Division of Gastroenterology and Hepatology in the National University Hospital, Singapore. He is also a Professor in the Yong Loo Lin School of Medicine, National University of Singapore.

Prof Lim attained his basic medical degree with honours (MBBS Hons) from the University of Monash, Melbourne, Australia. He later pursued a doctorate degree (MD) in Monash and was awarded the FRACP (Australia), FRCP (London), FAMS (Gasteroenterology, Singapore).

He is considered a master clinician having trained over 40 gastroenterologists and hepatologists, and is regularly referred difficult to treat liver cases. His main clinical work focuses on the treatment of viral hepatitis (esp. B and C), liver disease and liver cancer.

Prof Lim’s research activities include leadership in Hepatology research, which focuses on improving treatment for chronic hepatitis B and C, pathophysiology of hepatitis B disease, HBV virology, immunological mechanisms of HBeAg seroconversion, and loss of immune tolerance to hepatitis B virus. He also has an interest in pathophysiology and treatment of liver cancer, primary hepatocyte culture, hepatocyte function, drug related liver disease and non-alcoholic fatty liver disease.

Prof Lim has over 253 publications in peer-reviewed journals with a H-index of 51, and sits on the editorial board of Liver International Hepatology, International, J Viral Hepatitis, Alimentary Pharmacology and Therapeutics, and Lancet Gastroenterology and Hepatology. He has received over S$48 million in research grants.

Prof Lim also sits on the Advisory Board of Novartis Pharmaceuticals, Idenix Pharmaceuticals, Bristol Myers Squibb Pharmaceuticals and is on the Speaker’s Bureau for GlaxoSmithKline and Schering Plough Pharmaceuticals. Prof Lim has been an invited speaker at AASLD, EASL and APASL in 2013, 2014 and is a regular speaker at numerous International and Regional meetings on liver disease and viral hepatitis.

Prof Lim is also an Evidence Based Medicine (EBM) Champion, having founded the annual Asia Pacific EBM workshop in 2004 together with Prof Tony Dans from the Philippines which still runs yearly, and actively teaches and contributes to the development of EBM in Singapore.

Prof Lim is Council member, International Coaliltion for Eradication of Hepatitis B Virus (ICE-HBV), AASLD Asia Pacific Regional Council member, Co-chair ICE-HBV treatment subcommittee, and Co-chair combination therapy subcommittee HBV Forum.

Dr. Guan Huei Lee

Designations:

Senior Consultant, Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital
Senior Consultant, Liver Transplantation, National University Centre for Organ Transplantation, National University Hospital
Medical Director, Adult Liver Transplantation Programme, National University Centre for Organ Transplantation, NUH
Research Director, Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital

Qualifications:
MBBS (S’pore), MRCP (UK), FRCP Ed (UK), Ph.D. (S’pore)

Specialties:
Medicine, Organ Transplantation

Sub-specialties:
Gastroenterology ＆ Hepatology, Liver Transplantation

Special Interests:
Viral hepatitis, Liver failure, Liver transplantation, Liver cirrhosis, Fatty liver disease.

Biosketch
Dr. Guan-Huei Lee graduated from the National University of Singapore (NUS), and completed his advance specialist training in Gastroenterology in 2009. He received further training a clinical fellow at the Institute of Liver Studies, King’s College Hospital, London, focusing on liver intensive care. He received his PhD from NUS in 2014. He was awarded Fellowship of the Royal College of Physicians of Edinburgh in 2015.

Dr. Lee has helped to strengthen the clinical and research capabilities of the Division of Gastroenterology & Hepatology, National University Hospital (NUH), particularly in the management of liver failure and liver transplantation. He is serving dual role as Deputy Head, Division of Gastroenterology & Hepatology, and Medical Director, Adult Liver Transplantation Programme, National University Centre for Organ Transplantation (NUCOT).

Dr. Lee’s research work centers on the application of innovations in technology and biomedical science to the field of Hepatology. His current work focuses on developing novel targets to achieve functional cure of chronic hepatitis B. His other research interest includes liver failure, liver cancer, fatty liver and chronic hepatitis E. He has published multiple peer-reviewed research articles in such top-tier journals as the Gastroenterology, Gut, and Molecular & Cellular Biology. His research work has been presented at the major meetings of such organisations as the APASL, EASL, ILTS, and AASLD. He is an investigator of several competitive research grants including the Translational & Clinical Research Flagship (TCR) Programme grant, Clinician Scientist-Individual Research Grant (CS-IRG) and was awarded the NMRC Clinician Scientist Award (CSA).

Personal hobbies and interests: Reading, Tennis, Photography, Hiking and Mountain Climbing.

Dr. Daniel Huang

Qualifications:
MBBS (S’pore), MMED (Int Med)(S’pore), MRCP (UK)

Biosketch
Dr Daniel Huang graduated from the Yong Loo Lin School of Medicine, National University of Singapore, and did his postgraduate residency training in NUH. He completed his fellowship in Gastroenterology and Hepatology, and was certified by the Specialist Accreditation Board of Singapore.

Dr Huang has a keen interest in liver transplantation, and is a member of the liver transplant team at the National University Hospital, Singapore. He is also proficient in diagnostic and therapeutic endoscopy.

Dr Huang’s research interest is in hepatocellular carcinoma oncogenesis in the setting of NAFLD and hepatitis B, and performs translational and clinical research in these areas.

Area of Interest:

Hepatocellular carcinoma
Liver transplantation
Non-alcoholic fatty liver disease
Hepatitis B

Dr. Mark Muthiah

Qualifications:
MBBS (S’pore), MRCP (UK), M.Med (Int Med, S’pore).

Biosketch
Dr Mark Muthiah is a Consultant specialising in Gastroenterology and Hepatology at the National University Hospital, Singapore. He graduated from the Yong Loo Lin School of Medicine, National University of Singapore, and did his postgraduate residency training in NUH. He completed his fellowship in Gastroenterology and Hepatology, and was certified by the Specialist Accreditation Board of Singapore in 2016.

Dr Muthiah has a keen interest in liver transplants, and is a member of the liver transplant team at the National University Hospital, Singapore. He is also skilled in diagnostic and therapeutic endoscopy, and is involved in colon cancer screening and endoscopic mucosal resection (EMR) of colon polyps.

Dr Muthiah’s research interest is in cellular therapies to reverse liver fibrosis and promote liver regeneration, and is actively involved in basic and translational research on this subject. He is also the principal investigator for ongoing studies in the field of liver cirrhosis and liver transplantation. He has received awards for his research at both regional and international conferences.

Dr Muthiah is actively involved in medical education for undergraduates, postgraduates, dentistry students, and pharmacy students. He has received numerous teaching awards from NUH, as well as the Outstanding Tutor Award from the Medical Student Society at the Yong Loo Lin School of Medicine.

Dr. Prem H Thurairajah

Qualifications:
MBBS (India), MRCP (UK), PhD (UK)

Biosketch
Dr. Thurairajah graduated from Kasturba Medical College in India in 1997. He subsequently pursued training in Internal Medicine in the United Kingdom which culminated with membership to the Royal College of Physicians (MRCP) in 2002. He trained in Gastroenterology and Hepatology at the West Midlands Deanery, Birmingham, UK and completed two fellowship stints, his first in Transplant Hepatology at the Liver Unit at Queen Elizabeth Hospital in Birmingham and his second in Hepatobiliary endoscopy (ERCP and EUS) at the University College of London (UCL) before obtained his Completion of Certificate in Specialist Training (CCST) in 2011. He completed a period of research leading to a Doctorate in Philosophy (PhD) in the field of Hepatitis C in 2010. He is well published in peer reviewed journals and continues to engage in clinical research.

He worked as a Consultant Transplant Hepatologist at St. James University Hospital, Leeds, UK in 2012 before moving to the Liver Transplant Unit at the University of Kentucky, USA as an Assistant Professor in Medicine where he served for 2 years. He moved to Singapore in 2014 and worked at Changi General Hospital , where he set up a treatment programme for Chronic Hepatitis C and served as the Director of Hepatology.

Dr. Chee Cheng Ean

Dr. Chee Cheng Ean graduated from the University College London (UCL) Medical School, London, UK with a Bachelor of Science (Hons) in Tumour Biology in 2001 and MBBS (Lond) in 2004. She then pursued her post-graduate training in the US by completing her residency in Internal Medicine (2008) and fellowship in Haematology and Oncology (2011) at the Mayo Clinic in Rochester, Minnesota. She was also appointed as Chief Fellow of the Mayo Clinic Haematology/Oncology Fellowship Program and promoted to Assistant Professor of Medicine and Oncology during her time at Mayo Clinic. Dr Chee subsequently joined the Division of Haematology/Oncology at Case Western Reserve University in Cleveland, Ohio, USA as an attending physician and Assistant Professor of Medicine.

Her clinical research portfolio includes a novel biomarker study in colorectal cancer which was awarded institutional and national grant funding. She also developed and was Principal Investigator and national study chair of a Phase I/II US cooperative group clinical trial of a Wee1 inhibitor in pancreas cancer which received full support and endorsement by the Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) and Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) in the US. Her work in pancreas cancer lead to her appointment as the ECOG representative to the Pancreatic Cancer Task Force of the NCI Gastrointestinal Steering Committee. She has many publications in peer-reviewed journals and has been invited as a journal reviewer in her field.

Dr. Chee is a specialist in medical oncology and currently practices as a senior consultant medical oncologist and clinician scientist, and also holds the Deputy Director (Clinical) position at the National University Cancer Institute, Singapore. She is board certified by the American Board of Internal Medicine (ABIM) in Internal Medicine, Medical Oncology and Haematology.

Dr. Chee’s interests are in cancers of the gastrointestinal (GI) tract which includes colorectal cancer, liver and pancreas cancers, cancers of the biliary tract, stomach and oesophageal cancers. She is also interested in drug development of novel agents and phase I trials.

Prof. Rohit Loomba

Dr. Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic steatohepatitis (NASH), and non-invasive assessment of NAFLD using advanced imaging modalities.

Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome. This integrated approach has led to several innovative applications such as establishment of MRI-PDFF as a non-invasive biomarker of treatment response in early phase trials in NASH, which has now been adopted in more than 50 clinical trials conducted worldwide. He holds a patent on non-invasive biomarkers of NASH and fibrosis.

His research is funded by the National Institutes of Health including three R01s, three U01 (two NIDDK and one from NIAAA), core director of P30 (NIDDK) and project director P01 (NHLBI) grant mechanisms, Foundation of NIH, National Science Foundation as well as several investigator initiated research projects funded by the industry. He is the Principal Investigator, UCSD, for the NIDDK-sponsored NASH Clinical Research Network. He served as the elected Chair of the NAFLD, Special Interest Group of the American Association for the Study of Liver Diseases. And is the elected member to the National Board of Directors of the American Liver Foundation.

He serves on the Editorial Board of Gastroenterology, Journal of Hepatology, GUT and Nature Reviews in Gastroenterology and Hepatology. He recently completed a 5-year term as the Deputy Editor of HEPATOLOGY, the official journal of the AASLD. Currently, he serves as the co-Editor of Alimentary Pharmacology and Therapeutics, an international journal in the field of gastroenterology and Hepatology.

Dr. Loomba has published more than 350 manuscripts and has an H-index of 99. He is among the top 1% of the globally highly cited scientists across all fields in 2019, 2020 and 2021 by Web of Science. He is an elected member of American Society of Clinical Investigation.

Prof. Man Fung Yuen

MD, PhD, DSc

Professor Yuen is now the Chair and Chief of the Division of Gastroenterology and Hepatology in the University of Hong Kong. He obtained his first bachelor degree of medicine in 1992. He further pursued his academic excellence through the achievement of obtaining 3 doctoral degrees including Doctor of Medicine with Sir Patrick Manson Gold Medal in 2001, Doctor of Philosophy in 2005 and Doctor of Science in 2017.

Professor Yuen’s research interests include prevention, natural history, serology, virology and treatment of chronic hepatitis B and C, and hepatocellular carcinoma. He is one of the top internationally renowned researchers in the field of hepatitis B disease. He has now published more than 490 papers in world renowned medical journals including New England Journal of Medicine, Lancet, Nature Medicine, Lancet Infectious Diseases, Lancet Oncology.

As a world-class clinician scientist, Professor Yuen is now leading most of the international trials examining new drugs including antiviral and immunomodulatory agents for the treatment of chronic hepatitis B. He is also actively performing cutting edge research on novel markers for hepatitis B infection and occult hepatitis B infection.

With all these international academic and professional achievements, Professor Yuen is an invited member serving as key opinion leader for several international coalition committees on hepatitis B disease.

Prof. Glenn Bonney

A/Prof Glenn Kunnath Bonney is the Director of Research, Department of Surgery at National University Hospital and the Director of SurgiCAL ProtEomics Laboratory, National University of Singapore. He attained his undergraduate medical degree in 2002 (MB ChB) from the University of Leeds, United Kingdom. Having completed Basic Surgical Training he was awarded Membership of the Royal College of Surgeons of England (MRCS) in 2006, he undertook a postgraduate research degree at Cancer Research UK to identify markers in bile for malignancy of the liver, while continuing clinical work at the Hepatobiliary and Transplantation Unit at St James’ University Hospital, Leeds. His proteomic based research culminated in a Doctorate of Medicine (MD) in 2008.

Having obtained a National Training Number, he subsequently undertook Higher Surgical Training in Birmingham, doing his specialist training at the University Hospitals of Birmingham, one of the largest liver transplant, liver and pancreas resection units in Europe. He became a Fellow of the Royal College of Surgeons of England in 2014.

He has numerous publications, presentations and invited lectures in liver transplantation, hepatocellular carcinoma, colorectal liver metastasis and pancreas cancer. With this experience, he was awarded a grant by the Royal College of Surgeons of England to pursue a 1 year fellowship for the investigation of the molecular biology of Hepatocellular Carcinoma at the National University Hospital Singapore (2013/14). On returning to the UK, he completed his surgical training and following a period as a Hepatobiliary and Transplant Surgeon, he returned to the National University Hospital Singapore.

A/Prof Bonney’s primary interest is in surgery for primary and secondary malignancies of the liver, pancreas and gallbladder, donor/recipient matching for liver transplantation and extending donor criteria. His clinical research has resulted in him receiving the Presidential Award of the International Hepatopancreaticobiliary Association (Seoul 2014).

Prof. Pei-Jer Chen

Graduate Institute of Clinical Medicine, National Taiwan University and Hospital.
No 7 Chung-Shan South Road,
Taipei, Taiwan

Professor Chen was appointed Director of the Hepatitis Research Center at the National Taiwan University Hospital in Taipei in 2001-2003, and now the faculty for Graduate Institute of Clinical Medicine, National Taiwan University. He was the President of Taiwan Association for Study of the Liver (TASL) from 2012 to 2013. He served as the President of Taiwan Society of Virology from 2016-2018.

His research interests focus on the molecular virology and immunology of hepatitis viruses, and the genetic and genomic study of hepatocellular carcinoma. Professor Chen’s clinical research covers the natural history of chronic viral hepatitis and hepatocellular carcinoma, and also explores and conducts new therapies and trials for both diseases. He has published over 630 articles in the areas of hepatitis and hepatocellular carcinoma.

He serves in the Editorial Board of Gastroenterology between 2017-2019. From 2001 to 2006 and then 2010-2011, was a member of the editorial board of the journal Hepatology and is reappointed from 2019-2021. In 2000, Professor Chen was awarded the International Research Scholar in Infectious Diseases by the Howard Hughes Medical Institute for a period of five years. He has been elected into Academia Sinica in year 2006, and become the TAWS member in year 2011.

Prof. Ann-Lii Cheng

Professor Ann-Lii Cheng is a Distinguish Professor at the National Taiwan University and Emeritus Superintendent of the National Taiwan University Cancer Centre. He remains an attending physician in the Department of Onctology and Internal Medicine, National Taiwan University Hospital.

He has contributed significantly to the basic knowledge and clinical application of molecular targeted therapy and immunotherapy in hepatocellular carcinoma (HCC). Living in the part of the world plagued by HCC, Prof. Cheng has devoted his career to substantiating a solution. Since 2004, he has been involved in the development of sorafenib and lenvatinib, two pivotal drugs in the first-line treatment of HCC, and recently the discovery of a new regimen, atezolizumab plus bevacizumab, which is considered an epoch-making breakthrough in this field. His research team at National Taiwan University has been recognized as one of the most prominent translational research groups in exploring the frontier of HCC treatment.

Prof. Toh Han Chong

Dr Toh is Senior Consultant and former Head at the Department of Medical Oncology and now Deputy Medical Director (Strategic Partnerships), National Cancer Centre, Singapore. He graduated from the University of London, UK with an intercalated Bachelor of Science in ‘Infection and Immunity’ from St Mary’s Hospital Medical School and qualified as a medical doctor from University of Cambridge, UK. Dr Toh obtained his Fellowship of the Royal College of Physicians in 2003. He received his medical oncology fellowship training at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, USA and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. Dr Toh is also alumni at the Harvard Business School. He is currently the vice-chairman of the Oncology Academic Clinical Program (ACP) for Education.

He is a recipient of the National Clinician Scientist Award for his pioneering work in cell therapy for cancer. He conducted the first cancer vaccine and T cell therapy clinical trials in Singapore, and continues to work actively in the field of cancer immunotherapy, immunology and inflammation. He also had a strong interest in drug development for gastrointestinal cancers including colon and liver cancer. Dr Toh is an Associate Professor and College Master at the Duke-NUS Medical School. He is also an adjunct Principal Investigator at the Institute of Molecular and Cell Biology, A*STAR. He was a council member in the Singapore Medical Association and the Singapore College of Physicians.

Prof. Hashem el-Serag

Hashem B. El-Serag, M.D., M.P.H.
Margaret M. and Albert B. Alkek Professor and Chair Department of Medicine
Baylor College of Medicine, Houston, Texas

Dr. El-Serag obtained his medical degree from Al-Arab Medical University in Libya, completed his internship and residency in internal medicine (1995) at Greenwich Hospital, Yale University, Connecticut, and completed a fellowship in gastroenterology (1997) at the University of New Mexico, Albuquerque, New Mexico, where he also earned a master’s degree in public health (1998). In 1999, Dr. El-Serag joined the Michael E. DeBakey VA Medical Center and Baylor College of Medicine (BCM) in Houston, where he later became Chief of the Section of Gastroenterology & Hepatology (2007-2016). In 2017, he was appointed as Chair of the Department of Medicine at BCM.

Dr. El-Serag’s research focuses on the clinical epidemiology and outcomes of several digestive disorders, including Barrett’s esophagus, esophageal adenocarcinoma, hepatocellular carcinoma and hepatitis C. He has obtained >60 funded research grants including those from NIH, VA and Cancer Prevention Research Institute of Texas (CPRIT). He has >540 published papers to his credit including those published in New England Journal of Medicine, JAMA, Annals of Internal Medicine and Gastroenterology. His national leadership roles included Editor-in-Chief for Clinical Gastroenterology and Hepatology (2012-2017) and President of American Gastroenterological Association (2019). Dr. El-Serag’s has been selected into the American Society for Clinical Investigators (ASCI) and American Association of Physicians (AAP).

Dr. Asim Shabbir

Asst Prof. Asim Shabbir is a Senior Consultant with the Division of General Surgery (Upper Gastrointestinal Surgery) at the National University Hospital, Singapore. He is also Head of General Surgery at Alexandra Hospital.

He completed his basic and advance surgical training at NUH, Singapore. He was awarded fellowships from Royal College of Surgeons of Edinburgh and was accredited a surgical specialist by the Specialist accreditation board in 2007. In 2009, he did a clinical fellowship on Gastric cancer management with special interest in laparoscopic surgery for gastric cancer at the Seoul National University Hospital, South Korean. In 2010, he trained at Eda Hospital, I Shou University Kaohsiung, Taiwan in Bariatric and Metabolic surgery and was awarded as Fellowship.

Asst Prof. Asim’s specialty is general surgery and his special interests are upper gastrointestinal surgery, bariatric & metabolic surgery, advance endoscopy and laparoscopic surgery. He has been active in international as well as local meeting of his interest. His research interest includes obesity, surgery for type 2 diabetes and gastric cancer. He won the Best free paper award for his presentation “Laparoscopic Roux-en-Y Gastric Bypass for the Treatment of Type II Diabetes Mellitus in Chinese Patients with Body 25-35kg/m2at Asia Pacific metabolic bariatric surgical society meeting 2010. He has published in reputed journals in his field of interest.

Prof. Jia Jidong

Jidong Jia is currently Professor of Medicine, Director of Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Professor Jia is the immediate past President of the International Association for the Study of the Liver(IASL), past President of Asian Pacific Association for the Study of the Liver (APASL 2009-2010) and Chinese Society of Hepatology (CSH 2006-2012). Professor Jia also serves as Associate Editor for Hepatology International and served as Associate Editor for Journal of Gastroenterology & Hepatology and Liver International. As a hepatologist, his clinical interests include viral, cholestatic/autoimmune and genetic liver diseases. His research work focuses mainly on cellular and molecular biology of the extracellular matrix of the liver and the pathogenesis and therapeutic study of experimental liver fibrosis. In addition, Dr. Jia has been PI or sub-PI for many clinical trials and also heavily engaged in the teaching of clinical research methodology for residents and fellows in clinical medicine. He has authored or co-authored more than one hundred papers published in national and international journals including Gastroenterology, Gut, Hepatology, and Journal of Hepatology.

Dr. Jonathan Lee

Consultant, Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital

Dr. Alfred Kow

Dr. Alfred Kow is a practicing surgeon at the Division of Hepatobiliary & Pancreatic Surgery, NUH.

Dr. Kow obtained his Master of Medicine (Surgery), Master of the Royal College of Surgeons of Edinburgh and Ireland diplomas in 2005 and subsequently, completed his advanced surgical training in Tan Tock Seng Hospital. In 2009, he obtained his Fellowship of the Royal College of Surgeons of Edinburgh (General Surgery) in Hong Kong. He was also accorded Specialist accreditation in General Surgery by Ministry of Health, Singapore in the same year.

He received the funding from National University Health System in 2010 to undergo fellowship training in living donor liver transplantation (LDLT) and hepatobiliary & pancreatic surgical oncology in Samsung Medical Center & Samsung Cancer Center, Sungkyunkwan University School of Medicine in Seoul, South Korea. During his one-year stay in Korea, he authored or co-authored 6 peer-reviewed journals.

He has also published numerous articles on pancreatic surgery, liver surgery and biliary surgery at peer reviewed journals and written a book chapter. Dr. Kow is strongly interested in liver transplantation (both deceased donor and living donor) as well as minimally invasive (laparoscopic) surgery for hepatobiliary and pancreatic conditions.

In addition, Dr. Kow has keen interest in research activities involving development of surgical techniques in HPB surgery and outcome of surgical treatment for HPB malignancies. The other areas that he is keen to research on are liver transplantation, peri-transplant management and outcome studies.

Furthermore, he is also actively developing research to help improve surgical education and training for both undergraduate and postgraduate setting. Most of his research work on education aim to understand the art and science behind training junior doctors to be excellent surgeons for the future. He has previously won grants to study the use of mobile applications in teaching patient safety in surgery.

Dr. Raghav Sundar

Dr. Raghav Sundar is a clinician-scientist specialising in gastrointestinal oncology. He is a consultant medical oncologist at the National University Cancer Institute, Singapore, treating patients with gastrointestinal malignancies including colorectal, gastric and hepatobiliary malignancies. He also specialises in experimental therapeutics and early phase clinical trials, and is a part of the Phase 1 clinical trials team. He underwent fellowship training at the Drug Development Unit, Royal Marsden Hospital, UK. His research interest is in genomics of gastric cancer.

He studies the interaction between the tumor epigenome and the immune microenvironment. His work has identified predictive biomarkers of systemic therapy in gastric cancer as well as potential therapeutic targets. His studies incorporate contemporary technology such as spatial transcriptomics and machine-learning. Another area of research interest is in chemotherapy induced peripheral neuropathy. As a translational clinician-scientist his works arches across several domains, collaborating with engineers, bioinformaticians, laboratory scientists, pharmaceutical and industry partners. He has published over 50 manuscripts, in high impact journals such as Cancer Discovery and Gut and secured over $4 million in grant funding to date.

Professor. Teerha Piratvisuth

Professor of Medicine, Prince Songkla University, Hat Yai, Thailand and Director of NKC Institute of Gastroenterology and Hepatology Songklanagarind Hospital, Hat Yai.

Professor. Teerha Piratvisuth is affiliated to NKC Institute of Gastroenterology and Hepatology, Prince of Songkla University, where he is currently working as Professor. He has authored and co-authored several national and international publications and also working as a reviewer for reputed professional journals. He has an active association with different societies and academies around the world. Professor. Teerha Piratvisuth major research interest involves NKC Institute of Gastroenterology and Hepatology.

Dr. James Fung

James Fung is a Consultant at the Department of Medicine, and the Transplant Hepatologist at the Liver Transplant Centre, Queen Mary Hospital, Hong Kong. He graduated from the University of Auckland School of Medicine in 1997. In 2011 he attained his Doctor of Medicine studying non-invasive assessment of liver fibrosis. He has published widely and is a regular reviewer for major gastroenterology journals and a regular speaker. His main research interest includes viral hepatitis, liver fibrosis, advanced liver disease, hepatocellular carcinoma, and liver transplantation.

Prof. Guadalupe Garcia Tsao

Guadalupe Garcia-Tsao, M.D., professor of medicine (digestive diseases), is the new president-elect of the American Association for the Study of Liver Diseases. Garcia-Tsao is a staff physician at the VA Connecticut Healthcare System, where she is chief of the Section of Digestive Diseases and program director of the Hepatitis C Resource Center. She is also director of the Clinical Core of the NIH-funded Liver Center at Yale. Garcia-Tsao earned her medical degree from the Universidad Nacional Autónoma de México and completed her internal medicine residency and gastroenterology fellowship at the Instituto Nacional de la Nutrición in Mexico City. She completed her training in hepatology at Yale and joined the faculty in 1989.

Prof. Rajender Reddy

Dr. Reddy is the Ruimy Family President’s Distinguished Professor of Medicine and Professor of Medicine in Surgery in the Division of Gastroenterology/Hepatology at the University of Pennsylvania in Philadelphia, Pennsylvania. He is the Director of Hepatology, Medical Director of Liver Transplantation, and the Director of the Viral Hepatitis Center.

Dr. Reddy received his medical education from Osmania Medical College in Hyderabad, India. He then completed a residency in internal medicine at NewYork Medical College Hospitals, a fellowship in Gastroenterology at East Tennessee State University College of Medicine, and a fellowship in Hepatology at the University Of Miami School Of Medicine. Subsequently he joined the faculty at the University of Miami and in October 2001, Dr.Reddy moved to the University of Pennsylvania to the current position.

A Fellow of the American College of Physicians, American College of Gastroenterology, and the Royal College of Physicians (UK), Dr. Reddy is also a Fellow and Councilor-at-Large of the American Association for the Study of Liver Diseases. He has held several Visiting Professorships at Medical Schools throughout the World. He has trained several fellows and mentored numerous research assistants throughout his career.

Dr. Reddy has authored or co-authored over 350 peer-reviewed papers on a spectrum of hepatobiliary topics that include liver transplantation, chronic C viral hepatitis, HIV and the liver, and hepatocellular carcinoma. In addition, he has edited and contributed to several text books, and has participated in numerous scientific presentations at National and International meetings. He serves on the editorial boards of prestigious journals such as Liver Transplantation, Hepatology, Liver International, and is an ad-hoc reviewer for several journals.

Dr. Reddy also has participated in a number of clinical trials that have advanced the understanding of the therapy of chronic viral hepatitis. He has been the recipient of both federal and non-federal funding for clinical research. His current research interests include areas of liver transplantation, viral hepatitis, and hepatocellular carcinoma.

Prof. Pietro Lampertico

Pietro Lampertico, MD, PhD, is an Associate Professor of Gastroenterology, Director of the Gastroenterology and Hepatology Division, and Head of the A.M. e A. Migliavacca Center for the Study of Liver Disease at the University of Milan in Italy. He graduated from the State University of Milan with degrees in medicine and surgery and performed postdoctoral research in the Department of Experimental Pathology at Tulane University in New Orleans, LA. Upon returning to Milan, he completed training in liver diseases and internal medicine. He received his PhD in clinical methodology from the University of Milan. Dr Lampertico’s clinical and research interests include viral hepatitis, metabolic liver disorders, autoimmune liver disorders, hepatocellular carcinoma, hepatic fibrosis, portal hypertension, fatty liver disease, liver transplantation, and alcoholism. He has special expertise in caring for patients with chronic cirrhosis due to untreated hepatitis B virus (HBV) infections, optimizing long-term outcomes for cirrhotic patients undergoing antiviral treatment, and managing antiviral resistance to oral nucleos(t)ide analogues. A well-published scholar, Dr Lampertico serves as a reviewer for numerous top-tier journals in his field, including Lancet, Gastroenterology, Hepatology, Gut, and the Journal of Hepatology. He is a member of the American Association for the Study of Liver Disease (AASLD), the European Association for the Study of the Liver (EASL), the Italian Association of Liver Study (AISF), and the Italian Society of Gastroenterology (SIGE), among many other professional societies. He speaks frequently at international conferences about liver diseases, especially on the natural history of HBV and antiviral treatment, and is involved in national and international HBV clinical trials.

Prof. Patrick Marcellin

Patrick Marcellin is Professor of Hepatology at the University of Paris and Head of the Viral Hepatitis Research Unit in Hôpital Beaujon, Clichy. He earned his medical degree from the University of Paris and undertook postgraduate training in both internal medicine and gastroenterology-hepatology at the Assistance Publique-Hôpitaux de Paris. Professor Marcellin completed research fellowships in immunology (College of Physicians and Surgeons at Columbia University, New York City, USA) and virology (Institut Pasteur, Paris). He also holds a PhD in virology. Since 1984, he has been actively involved in laboratory and clinical research on viral hepatitis and liver diseases. His major focus has been on viral hepatitis therapy, and as such he has been the principal investigator on initial trials of first interferons and antivirals and on several pivotal studies investigating therapies for chronic hepatitis B and C. He published more than 500 articles in the best journals (NEJM, Lancet, Gastroenterology, Hepatology, J Hepatol…). Professor Marcellin was a member of the Scientific Committee of EASL and organised the EASL Consensus Conference on Hepatitis C in 1999 and the EASL Consensus Conference on Hepatitis B in 2002. He was the Chairman of the panel on the 2009 EASL hepatitis B guidelines. He is the President of APHC that has organised the Annual Paris Hepatitis Conference (PHC) since 2004.

Dr. Kamarjit Singh Mangat

Dr Kamarjit qualified in 1993, UK, then completed Basic Surgical Training in UK and Australia, obtaining Fellowship of Royal College of Surgeons, London. Interest in Interventional Radiology led to Radiology training, Fellowship of the Royal College of Radiologists UK and a fellowship in Interventional Radiology. Specialist interest in Hepatobiliary Radiology led to a sabbatical at University of California, San Diego.

From 2005 to 2014 he was a Consultant Radiologist at Queen Elizabeth University Hospital Birmingham, UK working with the Liver Unit (one of the largest in the world), and also Birmingham Children’s Hospital. From 2010 to 2014 he was the Head of Radiology. In 2014 he was invited to lead liver radiology services at National University Hospital Singapore, and is currently a Senior Consultant Radiologist and Research Director for the Radiology Department.He has expertise in all forms of liver imaging and intervention, in particular TIPS, post-transplant intervention, biliary procedures, Budd-Chiari syndrome and minimally invasive treatment of tumours using ablation techniques, TACE and SIRT.

Dr. William Pirjamali

William received an MSc in Genetic Counseling from McGill University and has been working with Fulgent Genetics since 2017. He collaborates with clinicians and research partners all over the world to provide a broad portfolio of clinical genetic tests. Fulgent’s catalog of genetic tests covers a wide range of clinical subspecialties, and everything from prenatal testing to adult onset disorders, including liver disease. William has a special interest in Fulgent’s HelioLiver test, a novel multi-analyte blood test combining cell-free DNA methylation patterns and protein tumor markers to screen for hepatocellular carcinoma.

Prof. Thomas Yau

MD(HK), MBBS (HK), MRCP (UK), FRCP(London), FHKCP (Med Onc), FHKAM (Medicine)

Clinical Associate Professor in Medical Oncology
University Department of Medicine
Li Ka Shing Faculty of Medicine
The University of Hong Kong

Dr Yau graduated from the University of Hong Kong and started his medical oncology training initially at Queen Mary Hospital, Hong Kong. He was later employed as Specialist Registrar and Clinical Research Fellow at Royal Marsden Hospital, London. He is currently Associate Professor in Department of Medicine, The University of Hong Kong and Principal Investigator in State Key Laboratory for Liver Disease.

His main research interests are gastrointestinal oncology, early phase clinical trials and translational research. He pioneered Hong Kong Liver Cancer classification and is actively involved in the global drug development in hepatocellular cancer. He had published more than 120 peer-review publications with articles in various leading oncology journals, namely Lancet, Lancet Oncology, Cell Stem Cell, Gastroenterology, Hepatology and Clinical Cancer Research. He had also delivered more than 180 invited regional and international lectures. He currently serves as associate editor and the editorial board members of many international peer-reviewed journals.

He is currently the International Member of US NCI Hepatobiliary Task Force, Vice President of Asia Pacific Neuroendocrine Tumour Society, International Faculty Board Member of International Association of Surgeons Gastroenterologist and Oncologists, General Secretary of Hong Kong Liver Cancer Foundation, and member of many international professional societies.

He is also the council member of Hong Kong Sustainable Council and the advisor of various Hong Kong Government advisory committees.

Prof. Robert Gish

Dr Gish was first in Pharmacy School at the University of Kansas and then obtained his medical degree from the University of Kansas Medical School in Kansas City, Kansas. He completed a 3-year internal medicine residency at the University of California, San Diego, and a 4-year gastroenterology and hepatology fellowship at the University of California, Los Angeles which included transplant medicine.

Dr. Gish is a fellow of the American Association for the Study of Liver Disease, the American Society of Transplantation and the American College of Physicians.

He has served on the editorial boards of American Journal of Gastroenterology, Hepatology, Journal of Hepatology, Digestive Diseases and Sciences, and Gastroenterology, among many others. He has co-authored a public health policy for liver health in Vietnam focusing on HBV and is also assisting with the development of viral hepatitis health care policies in Georgia, Armenia, and the Philippines. He was a major early contributor to decipherment methods for the detection of hepatitis B and C virus and characterizing its epidemiology and clinical presentation in humans. He was involved in studies that led to the genotypic classification strategies and methods now in use worldwide. He has published more than 700 original articles, review articles, abstracts, and book chapters.

Robert G. Gish, MD, is currently an Adjunct Professor of Medicine at the University of Nevada Schools of Medicine in Las Vegas and in Reno. He serves as an Adjunct Professor of Pharmacy at Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD. In addition, he is also Medical Director of the Hepatitis B Foundation in Doylestown, Pennsylvania.

Dr. Janus Ong

Medical Education:
University of the Philippines College of Medicine.
Internal Medicine Residency at the Yale Primary Care Internal Medicine Residency Program
Gastroenterology Fellowship at the Cleveland Clinic Foundation.
Clinical Hepatology Fellowship at the National Institutes of Health in Bethesda, Maryland
Master of Public Health from Johns Hopkins University Bloomberg School of Public Health.

Current Academic or Administrative Positions:
Clinical Associate Professor at the University of the Philippines College of Medicine.

Area of Research interests:
AFLD, hepatocellular carcinoma, Hepatitis B and C, and complications of cirrhosis.

Publications and Presentations:
Dr. Ong has published more than 50 research articles and over 60 research presentations to international meetings.

Dr. Ong has been active in liver disease research since his fellowship at the Cleveland Clinic. He subsequently worked at Liver Program of the NIDDK, NIH undr the mentorship of Dr. Jay Hoofnagle. After additional training in Liver Transplant at Inova Fairfax Hospital and Masters in Public Health at Johns Hopkins University, he worked as Staff Hepatologist at the Center for Liver Diseases, Inova Fairfax Hospital in Falls Church Virginia. Dr. Ong was highly active in Outcomes Research related to NAFLD, Viral Hepatitis and Hepatic Encephalopathy. Since 2007, Dr. Ong has joined University of the Philippines College of Medicine as a hepatologist and has been involved in a number of projects, including Organizing Committee of 2019 APASL in Manila Philippines.

Prof. Paul Yen

Dr. Yen currently is Professor at Duke-NUS Graduate Medical School in Singapore and Head of the Laboratory of Hormonal Regulation in the Cardiovascular and Metabolic Disorders Program. He also is Professor of Medicine at Duke University School of Medicine, Durham, NC and a member of the Duke Molecular Physiology Institute. He received his B.A. in Chemistry from Amherst College and his M.D. from Johns Hopkins. He completed his residency in internal medicine at University of Chicago and fellowship in endocrinology at National Institutes of Health, Bethesda, MD. He was formerly Assistant Professor at Harvard Medical School, Chief of the Neuro-endocrinology and Molecular Regulation Section of the Clinical Endocrinology Branch at NIDDK (at the National Institutes of Health, Bethesda, MD), and Associate Professor of Medicine and Pharmacology at Johns Hopkins University School of Medicine.

He has served on the editorial boards of Endocrinology, Molecular Endocrinology, and Thyroid. He also is a U.S. board-certified physician in internal medicine and endocrinology. He is listed as a top 2% scientist worldwide by Stanford University and a leading World Expert on thyroid hormone by Expertscape. He has served as an Asia-Oceanic Thyroid Association (AOTA) Council Member and the AOTA delegate to the World Thyroid Foundation and Singapore Representative to the International Iodine Global Network. He was awarded the 2020 Nagataki-Fujifilm Prize for his contributions to basic and clinical thyroid hormone research in Asia by AOTA. At Duke-NUS, he has served as Master of Sheares Medical College since 2010.

He also has served as the clinical faculty advisor for the Duke Overseas Volunteer Expedition (DOVE) program in which medical students deliver primary care in neighboring underdeveloped countries since its inception in 2010.. His laboratory uses molecular biological and genomic approaches to study hormonal regulation of transcription, autophagy, and metabolism as well as searching for ways to improve the diagnosis and treatment of non-alcoholic fatty liver disease (NAFLD), diabetes, obesity, and other metabolic disorders.

Prof. John E. Tavis, PhD

Professor of Molecular Virology
Saint Louis University (SLU)

My research focuses on the biochemistry and cell biology of the reverse transcriptase from the Hepatitis B Virus and on the effect of Hepatitis C Virus’ very high genetic diversity on its response to antiviral therapy and on disease induced by HCV infection. I am active in the international virology community, having organized the 2003 International Meeting on the Molecular Biology of HBV, served on the American Society for Virology program committee, chaired an American Cancer Society study section, served as a reviewer for many journals, and have recently been appointed to 3 national service positions: An academic editor for PLoS One, a permanent member of the VirB NIH study section, and a member of the American Cancer Society Council for Extramural Research. This experience has given me a broad perspective on virology in both the clinical and basic settings.

Dr. Carolina Boni

MD, Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

Dr. Boni is physician at the Azienda Ospedaliero-Universitaria of Parma and Contract Professor of Infectious Diseases at the University of Parma.

Dr. Boni’s research is mostly focused on the characterization of the immune mechanisms responsible for viral persistence and liver damage in chronic HBV infection with the final objective of developing new immune therapeutic strategies for chronically infected patients.

She has published 40 original articles (4556 citations; H index =26) and presented the results of her research in the field of hepatitis virus infections at several national and international meetings.

She provided original contributions to the HBV immune pathogenesis field, in particular for the characterization of the immunological correlates of protection in acute and chronic HBV infection and for the definition of new biomarkers to assess and predict the effect of a novel immune therapies.

Prof. Massimo Levrero

Professor of Medicine, Sapienza University, Centre de Recherche en Cancerologie de Lyon (CRCL) Lyon, France

Massimo Levrero is Professor of Medicine at the University Claude Bernard Lyon 1 (UCLB1), Lyon, France, and Praticien Hospitalier in the Service d’Hepatologie et Gastroenterologie – Hopital de la Croix Rousse – Hospices Civils de Lyon. He leads a Research Unit on” Epigenetics and Epigenomics of Hepatocellular Carcinoma”, at the Centre de Recherche en Cancérologie de Lyon (CRCL) – INSERM U1052 in Lyon, France. He also serves as Associate Member at the IIT – Sapienza Center for Life NanoScience (CLNS) in Rome and he is on leave of absence from the Department of Internal Medicine (DMISM) at the Sapienza University of Rome, where he had his research activity and academic practice in hepatology until 2014.

Professor Levrero trained and completed his residency at Sapienza before holding posts at the University Paris VI and the Institut Gustave Roussy in Paris. He has acted as Scientific Secretary of EASL (European Association for the Study of the Liver) and he currently presides the CSS12 study session on basic and translational research on viral hepatitis at the French National Agency for Research on AIDS and Viral Hepatitis (ANRS). He is a founding member and seats in the Governing Board of ICE (International Coalition to Eliminate HBV).

He is actively involved in clinical research and treatment of HBV and HCV chronic hepatitis, and he served as Network Coordinator and/or Primary Investigator in a number of research projects and clinical studies. HBV research focuses on the epigenetic regulation of cccDNA function and HBV replication, the identification of new targets for anti-¬‐viral therapy and on liver oncogenesis in HBV-¬‐ related hepatocellular carcinoma. Additional research interests include signal transduction and transcription in the liver; IFN transcriptome; chromatin modifiers in solid tumours development and progression.

Professor Levrero is the author of over 200 publications in peer-reviewed journals, including Nature, Nature Medicine, Nat Cell Biol, Nature Communications, Science, J Clin Invest, J Exp Med, Mol Cell, PNAS USA, Cancer Res, Oncogene, EMBO J, J Biol Chem, Sci Rep, Gastroenterology, J of Hepatology, GUT, Hepatology, J of Virology, Virology, J Gen Virol, J Infect Dis, Blood.

Prof. Fabien Zoulim

Medical Director of the Hepatology

Fabien Zoulim obtained his M.D. in Gastroenterology and Hepatology in Lyon Medical School in 1991. He has also obtained a PhD in Molecular and Cellular Biology and was trained as a post-doctoral researcher at Fox Chase Cancer Center in Philadelphia. He is Professor of Medicine at Lyon I University since 1997. He is currently Medical Director of the Hepatology Department at the Hospices Civils de Lyon, and Scientific Director of the Department of Immunology and Virology of INSERM Unit 1052 where he is leading the team on ‘Antiviral therapy of viral hepatitis’. Prof. Zoulim has served as an Associate Editor for Journal of Hepatology and is currently Associate Editor for Gut. He also served as an expert in the microbiology study section of the INSERM and is currently head of the clinical viral hepatitis study section at ANRS. He served as a Governing Board member of the European Association for the Study of the Liver (EASL). Prof. Zoulim received the William Prusoff award of the International Society for Antiviral Research. Furthermore, he has been the scientific coordinator of a European community-funded Network of Excellence on the management of antiviral drug resistance and is currently head of the ANRS “HBV cure” program in France. Fabien Zoulim is a recognised expert in the field of viral hepatitis and antiviral therapy. He has published more than 350 articles (H index 63, Web of Science).

Prof. Antonio Bertoletti

Antonio Bertoletti, MD is an expert in the field of viral hepatitis, with a specific interest in the immunopathogenesis of HBV infection. He began working in viral hepatitis as a medical student at the University of Parma (Italy). During his MD specialization (1991) in Infectious Diseases he spent two years at The Scripps Research Institute (La Jolla) characterizing for the first time the Hepatitis B virus (HBV) specific cytotoxic T cell response in man. He returned to the University of Parma, where he worked in the Department of Infectious Diseases as a Clinical Scientist continuing his study of human HBV specific T cells. Dr. Bertoletti then joined (1995) the MRC Unit in the Gambia, as Senior Immunologist, to study HIV-2 specific T cell Immunity before accepting a position of Senior Lecturer at “The UCL Institute of Hepatology” at University College of London (UK) (1997). In 2006 he moved to Singapore where he was the Director of Infection and Immunity Program at the Singapore Institute for Clinical Sciences (A*STAR) until 2013 before moving, as Full Professor, at the Emerging Viral Disease Program at Duke-NUS Medical School. He also maintains an Adjunct Position at the Singapore Immunology Network, (A*STAR). He won for two consecutive terms the Singapore Translational Research Awards (2013 and 2018). In 2015 he founded Lion TCR Pte (http://liontcr.com), a biotech company developing immune- based treatments for virus-related cancers (HBV-HCC and EBV related malignancies) and chronic viral infections. This immune therapy utilizes T cell receptors engineered T cells targeting viral antigens express in cancer cells. The company has been the first to initiate and run clinical trials (Phase I and II) for the treatment of HBV-related HCC relapses in liver transplant patients and in primary HCC in Singapore and China. At present he is Chairman of the Board and major shareholder. His current research is focus on the development of new immunological based therapies (TCR- redirected T cells) for the treatment of HBV chronic infection and Hepatocellular carcinoma and on the characterization of antiviral Immunity in chronic HBV patients. In the last 6 months, after the start of the COVID-19 pandemic, his laboratory has been actively involved in the characterization of SARS-COV2 specific T cell immune response (Le Bert et al, Nature 2020, 584: 457-62) in COVID-19 and SARS convalescent and healthy individuals.

Prof. Sharon Lewin

AO, FRACP, PhD, FAHMS

Professor, The University of Melbourne; consultant infectious diseases physician, Alfred Hospital and Royal Melbourne Hospital and a National Health and Medical Research Council (NHMRC) Practitioner Fellow.

She is an infectious diseases physician and basic scientist. She completed her medical degree and PhD in virology at Monash University in 1996 and her post-doctoral fellowship with Dr David Ho at Rockefeller University in 1999. Her research focuses on understanding why HIV persists on treatment and developing clinical trials aimed at ultimately finding a cure for HIV infection. She has also had a long standing interest in the natural history and management of HIV-HBV co-infection. She has published over 300 publications and given over 1200 major invited talks on HIV cure. She has received multiple national and international awards for her HIV-related research and community engagement. In 2014 she was named Melburnian of the Year and Clarivate Web of Science high citation researcher. She is President-Elect of the International AIDS Society and will be President in 2022-2024.

She leads a large national network funded by the National Health and Medical Research Council of Australia called The Australian Partnership in Research for Infectious Disease Emergencies (APPRISE) which focuses on pandemic preparedness and started in Australia in 2016. Scientists from the Doherty Institute were the first to isolate and share the SARS COV2 virus outside of China and have a broad program of research focused on testing, treatments and vaccines for COVID19.

Dr Willam Delaney

William Delaney, PhD joined Assembly as Chief Scientific Officer in May 2020. Prior to joining Assembly, he most recently served as Executive Director, Biology at Gilead. During his 20-year career at the company, he headed the Viral Hepatitis & Herpes Discovery Biology Groups and served as the Research Therapeutic Area Head for HBV. He began his career as a Research Scientist, Clinical Virology at Gilead and later transitioned into Drug Discovery where he held positions of increasing responsibility. Over the course of his career, he has contributed to the development of several marketed products, including Hepsera®, Viread®, and Vemlidy® for HBV and Sovaldi®, Harvoni®, Epclusa®, and Vosevi® for HCV. He earned a BS in Biotechnology from the University of Delaware and a PhD in Cell and Molecular Biology from the Penn State College of Medicine. In addition, he was a Postdoctoral Fellow at the Victorian Infectious Diseases Reference Laboratory (VIDRL), Department of Research & Molecular Development.

Dr. Shihyun You

Senior Director

Shihyun You, Ph.D. is a Senior Director heading HBV research at GlaxoSmithKline. She has more than 20 years of experience in viral infectious diseases and thirteen years of industry experience in the drug discovery and development including HCV and HBV. She earned a MS in genetic engineering from SungKyunKwan University, South Korea and a PhD on dengue virus replication from University of Kansas Medical Center. She obtained postdoctoral training focusing on HCV with Prof. Charlie Rice at the Rockefeller University.

Andrew Valliant

Chief Scientific Officer

Dr. Vaillant is the Chief Scientific Officer at Replicor Inc. He has more than 20 years of experience in the fields of nucleic acid chemistry, virology and drug development and is the discoverer of nucleic acid polymers (NAPs). Dr. Vaillant has authored numerous research publications, reviews, and patents on the use of NAPs in various infectious diseases. His research focuses on the development of NAPs to achieve functional cure of HBV and HDV and the role of HBsAg loss and transaminase flares in achieving functional cure of HBV. He was a postdoctoral fellow at the Montreal Neurological Institute and holds a Ph.D. in Cell Biology from the University of Ottawa.

Dr. Shahzada Khan

Dr. Shahzada Khan, a Senior Scientist at Gilead Sciences, has more than 15 years of biomedical research experience in an array of research fields including innate and adaptive immune responses to infectious agents, oxidative / nitrative stress responses, and viral / bacterial disease pathogenesis. Shahzada obtained his PhD in medical sciences from Kumamoto University Japan and postdoctoral training at Gladstone Institutes in San Francisco, CA. At Gilead Sciences, he is currently involved in discovery research and development of immunotherapeutic agents for treatment of chronic HBV infection.

Dr. Ram DasGupta

Ramanuj DasGupta joined A*STAR’s Genome Institute of Singapore (GIS) in 2014 where he is now a Senior Group Leader. DasGupta obtained his Ph.D. in Developmental and Stem cell Biology at the University of Chicago followed by postdoctoral studies at the Harvard Medical School. The major focus in the DasGupta laboratory is to explore fundamental mechanisms of cancer evolution and implement “Response-driven Precision Oncology” in the clinic by utilizing next-generation, multi-omic single cell and spatial transcriptomic technologies.

Dr. Gaston Picchio

Dr. Picchio joined Arbutus Biopharma in October 2018 and serves as the Company’s Chief Development Officer. Previously, Dr. Picchio was with Janssen R&D, bringing with him over thirty years of basic and clinical experience in the field of human virology, and sixteen years of industry experience dedicated to the development of antiviral drugs including drug approvals for the treatment of HIV (etravirine and rilpivirine) and HCV (telaprevir and simeprevir). In 2015, Dr. Picchio was a recipient of the Johnson Medal for the development of telaprevir and simeprevir and combinations thereof. Prior to joining Arbutus, Dr. Picchio served in various senior management positions at Janssen R&D, including Vice President—Scientific Innovation Infectious Diseases & Vaccines, Vice President—Hepatitis Disease Area Leader and Vice President—Clinical Virology Infectious Diseases & Vaccines. Dr. Picchio also spent time in academia working at the Scripps Institute in La Jolla, CA, on HIV and EBV pathogenesis. Dr. Picchio received a Masters in Molecular Biology from University Centro de Altos Estudios en Ciencias Exactas, Buenos Aires, and a PhD degree from University of Buenos Aires, Argentina.

Dr. Simon Fletcher

Simon Fletcher is an Executive Director at Gilead Sciences. He received his undergraduate and Ph.D. degrees from the University of Cambridge (UK) and performed post-doctoral studies at Roche. He then moved to Anadys Pharmaceuticals where he worked on developing immunomodulatory therapies to treat chronic hepatitis C virus (HCV) infection. In 2009, he moved to Roche where he led drug discovery and translational research teams working towards the development of a functional cure for chronic hepatitis B virus (HBV) infection. Since 2012, he has worked at Gilead Sciences, where he leads a group focused on developing novel therapies for HBV and other chronic viral infections.

Dr. Oliver Lenz

Oliver Lenz, PhD is Senior Scientific Director Clinical Microbiology and Immunology at Janssen Infectious Diseases, part of the Janssen Pharmaceutical Companies of Johnson & Johnson. He is the global virology lead for the development of Hepatitis B virus (HBV) therapeutics from pre-clinical through clinical development. Prior to his work in HBV he was involved in the discovery of the HCV protease inhibitor simeprevir which he supported subsequently through clinical development until post-approval. He obtained his PhD at the University of Marburg, Germany mainly working on hemorrhagic fever viruses and did a postdoctoral fellowship at the European Molecular Biology Laboratory (EMBL) at Grenoble, France on HIV GP41 structural biology. He is author of more than 70 peer reviewed papers.

Dr. Steve Hood

Steve Hood PHD, FRSB, GSK Senior Fellow.
Senior Scientific Director in Bioimaging at GSK

Steve Hood received a PhD in Molecular Toxicology from the University of Surrey in 1993 and joined Glaxo Group Research as an Industrial Post doc in the Molecular Biology department. 29 years and a couple of mergers later, Steve is now a senior Scientific Director in Bioimaging, responsible for the external imaging collaborations that are members of the Bioimaging Expertise Network (BEN). As part of this network, Steve is also Co-Director of the GSK Centre for Molecular Imaging (COMI) at the University of Illinois at Urbana Champaign, where he works closely with Professor Stephen Boppart and his team.

In addition to his “day job”, Steve has spent most of the last 2 decades working on GSK’s diverse oligo portfolio and has supported projects ranging from inhaled SiRNAs, TLR antagonists, DMD exon skippers (Prosensa) and ASOs for TTR and HBV with Ionis. Steve was also Industrial co-lead of the IMI COMPACT consortium that ran from 2012-17 and evaluated delivery mechanisms for oligos and peptides.

Dr. Filippo Canducci

Dr. Filippo Canducci graduated in Medicine at Catholic University in Rome in 2001, specialized in Clinical Microbiology at San Raffaele in Milano where after his PhD led his independent research team until when he left academia for industry. Before transitioning to pharmaceutical industry, Dr. Canducci has obtained the National Habilitation for Full Professor in Clinical Microbiology, he was invited as lecturer and speaker in many national and international meetings, published peer-reviewed papers in many prestigious journals including The Lancet, NEJM, PNAS, Nature Comm, Science Adv, JID, EID, AIDS, J of Immunology. After an MBA, he founded two startups and was a member of the scientific board of a Small Biotech focused on antibiotic discovery. He is now Project Leader for immunology and virology assets including TLR7 and Senior Medical Director at Roche.

Dr. Collins Oduor Owino

Collins is a final year doctoral student at the National University of Singapore, Department of Microbiology and Immunology, and based at the Genome Institute of Singapore. In addition, he holds a joint Master of Science degree in Infection Biology, Vaccinology, and Drug Discovery from the University of Basel (Swiss Tropical and Public Health Institute) and the National University of Singapore, as well as a bachelor’s degree in Biomedical Science and Technology (Medical Biotechnology Option) from Maseno University, Kenya.

Collins has a keen interest in understanding the interaction between viruses and human hosts and how we can harness this information to support the development of alternative antiviral therapies. His Ph.D. thesis was on identifying novel host factors that support Hepatitis B virus infection. He looks forward to continuing studying how different viruses use our resources to make us sick during his post-doctoral training.

Dr. Cameron M. Soulette

Cameron received his PhD from University of California where he developed and applied long-read RNA sequencing methodologies to investigate transcriptome alterations associated in lung adenocarcinomas. He joined Gilead Sciences in 2020 and has contributed to several projects and publications aimed toward utilizing long-read technologies to better characterize Hepatitis B Viral integrations observed in chronically infected patients.

Prof. Simone Strasser

Associate Professor Simone Strasser is a Senior Staff Specialist in the AW Morrow Gastroenterology and Liver Centre, and the Australian National Liver Transplant Unit at Royal Prince Alfred Hospital and the University of Sydney in Sydney Australia.

She is President of the Gastroenterological Society of Australia (GESA), a member of the Executive Council of the Asian Pacific Association for the Study of the Liver (APASL) and a member of the Educational Committee of the International Liver Cancer Association (ILCA). She has a major clinical and research interest in primary liver cancer, viral hepatitis, non-alcoholic fatty liver disease, advanced liver disease, and liver transplantation. She is Director of Hepatology Clinical Trials at RPAH leading clinical trials of new therapies for patients with liver disease and liver cancer.

Prof.Ajay Duseja

Dr Ajay Duseja is presently working as Professor in the department of Hepatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. He did his MBBS in 1988, MD (Internal Medicine) in 1992 and DM (Gastroenterology) from PGIMER, Chandigarh in 1996. For last 22 years, he is working as Faculty with focused research in the field of Hepatology (See Academic Qualifications).

He is Fellow of National Academy of Medical Sciences (FAMS), Fellow of American Association for the Study of Liver Diseases (FAASLD), Fellow of American College of Gastroenterology (FACG) and Fellow of the Society of GI Endoscopy of India (FSGEI) (See Academic Qualifications).

He is the National Convener of the Indian National Association for the Study of Liver (INASL) Task Force on Nonalcoholic Fatty Liver Disease (NAFLD), member of the Chronic Liver Disease Foundation (CLDF) NASH Committee (USA), member of the Asia- Pacific Working Party on NAFLD and member of the Gut and Obesity in Asia (GOASIA) working group. He is also an active member of the INASL Task Force on Hepatitis C virus, Hepatocellular carcinoma, Acute-on-Chronic Liver Failure and Drug Induced Liver Injury (See Miscellaneous).

He is author of more than 220 papers in reputed international and national journals including 22 chapters in the Gastroenterology and Hepatology text books (See Publications). His main areas of interest include nonalcoholic fatty liver disease (NAFLD) and acute-on-chronic liver failure (ACLF). He has total of 55 publications on NAFLD/NASH including 11 chapters on NAFLD in various text books (See Publications).

Prof.Shridhar Iyer

A/Prof Shridhar Iyer is a Senior Consultant, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, and Surgical Director and Senior Consultant in the Adult Liver Transplant Programme, National University Centre for Organ Transplantation, at the National University Hospital (NUH). He graduated from Grant Medical College, Bombay University, India in 1994. He then underwent training in Surgical Oncology at the Tata Memorial Hospital; Mumbai. He was admitted as a Fellow to the Royal College of Surgeons of Edinburgh, UK in 1999. He completed Advanced Specialty training in General Surgery at the National University Hospital in 2005 and admitted as a Fellow to the College of Surgeons, Academy of Medicine of Singapore.

As a recipient of the Human Manpower Development Programme (HMDP) scholarship in 2006, A/Prof Shridhar Iyer went to pursue a Fellowship in Liver surgery and Liver transplantation at the Chang Gung Memorial Hospital, Taiwan. He trained in different aspects of liver, biliary surgery and living donor liver transplantation. He has published over 60 articles in peer reviewed scientific journals and over 100 presentations at international meetings. His research interests are HPB diseases and different aspects of living donor liver transplantation and has secured several competitive grants.

He has a keen interest in surgical education and served as the programme director for general surgery residency programme from 2010 to 2018. He successfully led the first ACGME-I accreditation for General Surgery residency outside of United states. He Initiated, developed and designed a comprehensive surgical skills training curriculum for general surgery training.

He is the Founding Member of the Hepato-Pancreato-Biliary Association (Singapore).

He has led several quality improvement projects in the hospital including reducing length of stay and efficient discharge processes. He has developed clinical pathways and protocols for patients undergoing liver transplantation. He has contributed actively to the development of Adult Living Donor Liver transplant programme and Donor Surgery for Pediatric Living Donor Liver Transplant at the NUH.

Prof.Geoffrey Dusheiko

Geoffrey Dusheiko, FCP(SA) FRCS, is Emeritus Professor of Medicine at the Royal Free Hospital and University College London School of Medicine and Consultant Hepatologist at Kings College Hospital London, in London, UK.

After earning his MBBS degree from the University of Witwatersrand in Johannesburg, South Africa, Professor Dusheiko completed his internship at the Chris Hani Baragwanath Hospital in Johannesburg and his residency at Johannesburg Hospital. His fellowships were conducted at the Johannesburg Hospital Liver Unit and the National Institutes of Health, Maryland, and the University of Minnesota, USA.
Professor Dusheiko’s research interests include the management and treatment of HCV and HBV and small hepatocellular carcinoma; he has a special interest in research on viral hepatitis, especially viral genotyping, applied molecular virology, the natural history of chronic viral hepatitis and antiviral therapies. A member of several organisations, including EASL, AASLD and IASL, Professor Dusheiko is also a Fellow of the Royal College of Physicians, the Royal College of Physicians of South Africa, and the Royal College of Physicians of Edinburgh.

He previously served as Educational Councilor on the Governing Board of EASL for 4 years and was the recipient of the EASL Recognition Award in 2014. An advisor for the UK National Institute of Health and Care Excellence, Professor Dusheiko is an author of the World Health Organization’s HBV guidelines and he was a Director of the Skipton Fund, a UK ex gratia payment scheme for patients infected with HCV through contaminated blood products. He served as interim Deputy Director of the Blood Safety, HIV, viral hepatitis and STI Division of Public Health England in 2019.

He is a co-editor of Alimentary Pharmacology and Therapeutics, and has previously served on editorial boards for the Journal of Viral Hepatitis, Hepatology, Best Practice & Research Clinical Gastroenterology, and Gut among others. Professor Dusheiko has authored or co-authored more than 500 articles in international peer-reviewed journals or books.

Prof.Henry Chan

Professor Henry Lik Yuen Chan a Deputy Chief Hospital Manager, Head of Department of Internal Medicine, and Head of Division of Gastroenterology & Hepatology of Union Hospital in Hong Kong. He is also an Honorary Clinical Professor of Faculty of Medicine, The Chinese University of Hong Kong (CUHK).

Professor Chan has been a key investigator in over 30 international trials on antiviral treatment of chronic hepatitis B and C, and has advised 13 pharmaceutical and biotechnology companies in the drug development for viral hepatitis B cure. He is the global lead author in publications on peginterferon-alfa, peginterferon-lambda, telbivudine, tenofovir disoproxil fumarate and tenofovir alafenamide for the treatment of viral hepatitis B. He has received numerous local, national and international research awards, including Okuda Lectureship in Asia Pacific Digestive Week in 2018. He has published over 500 papers in peer-reviewed journals, and is awarded Highly Cited Researcher (Cross Field) by Clarivate Analytics in 2018 to 2020 for producing multiple top 1% cited papers under Web of Science. Professor Chan is an associate editor of Hepatology International and Seminars in Liver Disease, and has served as an associate editor for Journal of Hepatology in 2014-2019. He is the chairman of the Strategic Technical Advisory Committee on Viral Hepatitis for the Western Pacific Regional Office of World Health Organization since 2015.

He is currently a Global Council Member in International Association for the Study of the Liver (IASL). He was awarded Ten Outstanding Young Persons in Hong Kong in 2008 in recognition of his professional excellence and contribution to the community.

Prof.Chan Wah Kheong

Dr Chan is Professor of Medicine at the University of Malaya and Senior Consultant Gastroenterologist and Hepatologist at the University of Malaya Medical Centre and the University of Malaya Specialist Centre. He is a Member of the Academy of Medicine of Malaysia and a Committee Member for the Malaysian Society of Gastroenterology and Hepatology. He is the Scientific Co-Chair for the Virtual Asia Pacific Digestive Week 2021. He is a member of the Asia-Pacific Working Party on Non-Alcoholic Fatty Liver Disease, the Gut and Obesity in Asia (GO ASIA) Workgroup, the CAP Prognosis Study Group, and the Global NASH Council. He is Associate Editor for the Journal of Gastroenterology and Hepatology, a member of the Editorial Board for Clinical and Molecular Hepatology and is a reviewer for several international journals. He has published numerous full papers in peer-reviewed journals and presented in both local and international conferences. His main area of research interest is metabolic dysfunction associated fatty liver disease.

Prof.Kudo Masatoshi

Prof. Masatoshi Kudo, MD, PhD, studied Medicine at Kyoto University and graduated in 1978. Following this, he completed a clinical fellowship in Kobe City General Hospital followed by a research fellowship at the University of California Davis Medical Center in the USA and Kyoto University Graduate School of Medicine, from where he received his PhD in Medical Science in 1987. Professor Kudo is currently a Professor and Chairman at the Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine (since 1999) and the Executive Board Member of Kindai University.

Professor Kudo has published 1135 International scientific peer-reviewed papers in well regarded in addition to 990 domestic scientific papers. He has given 472 invited lectures in the area of his expertise on numerous occasions to international audiences. He serves as an Executive Council Board Member of the Liver Cancer Study Group of Japan (LCSGJ), Chairman of the Nationwide Survey Committee of LCSGJ, and a representative of the LCSGJ Head Office. Professor Kudo is also a Past President of the Japan Society of Ultrasonics in Medicine (JSUM) (2014-2020), Past President of the Asia-Pacific Primary Liver Cancer Association (APPLE) (2015-2017), Past President of WFUMB (2011-2013), Past President of AFSUMB (2016-2018), an Executive Board Member of the Japan Society of Hepatology (JSH), an Executive Board member of the International Liver Cancer Association (ILCA). He is currently a Steering Committee Member, as well as Vice Chair, of the Liver Cancer Special Interest Group (SIG), AASLD. He also serves as an Editor-in-Chief of LIVER CANCER (Karger). He was named a “Highly Cited Researcher” in 2019, 2020 and 2021 consecutively by Clarivate Analytics in the field of “Clinical Medicine”.

His research interest is “Diagnosis and treatment of HCC”. Professor Kudo is the first author of “Consensus based Practice Guideline of HCC Proposed by Japan Society of Hepatology” published in 2007, 2010, 2014 and 2021 revised version.

Prof.Mohammad Shadab Siddiqui

Assoc. Professor Mohammad Shadab Siddiqui studies Medicine at the Wake Forest University in North Carolina, USA. He has been with Virginia Commonwealth University, Richmond since 2012.

The focus of Prof. Siddiqui’s research is the nonalcoholic fatty liver disease (NAFLD) and liver transplantation. More specifically, he is interested in the relationship between cardiovascular disease and NAFLD and how that affects patient outcomes. His research follows the natural history of the disease process as patients go from mild or early phase disease to more moderate disease to chronic liver failure (i.e. cirrhosis) and finally liver transplantation. The emphasis is better understanding what are key drivers of clinical outcomes at each of these disease states and if doctors can develop measures to not only risk stratify patients better at each stage but also develop strategies to mitigate and potentially even reverse this risk. Prof. Siddiqui and his team are therefore, focused on developing better risk stratification strategies (i.e. biomarkers) and therapeutics to help improve outcomes in patients with all stages of chronic liver disease.

Prof.Markus Cornberg

Markus Cornberg is Professor Infectious Diseases with a focus on Hepatology and Deputy Director of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, Germany. Since 2019, he is Clinical Director Helmholtz Centre for Infection Research and Director of the Centre for Individualized Infection Medicine (CIIM). Prof. Cornberg is Medical Executive Director of the German Liver Foundation. Since 2007, Prof. Cornberg has coordinated the German guideline on the management of hepatitis B virus infection. From 2017 to 2020, he served on the Scientific Committee and Governing Board of the European Association for the Study of the Liver (EASL). He has been Associate Editor of the Journal of Hepatology since 2019. His basic science research focus is the investigation of cellular immune responses for disease progression and treatment response in patients with viral hepatitis. Prof. Cornberg has published >250 original scientific papers as well as review articles.

Prof.Tan Seok Siam

Dr Tan Soek Siam is the Senior Consultant and Head of Hepatology Department in Hospital Selayang. She obtained her Bachelor of Medicine (MB BCH BAO BA) from Trinity College, Dublin, Republic of Ireland and subsequently practice at St James Hospital, Monaghan General Hospital and St Collumcilles Hospital in Republic of Ireland from 1991-1995. Upon obtaining her MRCP from Royal College of Physician Ireland in 1995, Dr Tan Soek Siam return to Malaysia and started practicing at Ipoh General Hospital as Clinical Specialist in General Medicine and Gastroenterology. Subsequently, she did her fellowship in Liver Intensive Care and Transplantation at Institute of Liver Studies, King’s College Hospital, London in 2000-2001.
She is the Chairperson for the Working Committee for Medications Gastro and Hepato-Pancreato-Biliary of Ministry of Heath( since 2015), a trainer in Hepatology Subspecialty Training programme (since 2003), and a National Advisor in Hepatology for Ministry of Health since 2005. Dr Tan Soek Siam is also a member of the Expert Panel of Specialist Service “ Ask the Expert” at MyHealth Portal, and a member of Specialty Subcommittee for Gastroenterology and Hepatology of the National Credentialing Committee . She is the President-elect of Malaysian Society of Gastroenterology and Hepatology (2016-2018), a council member of College of Physician, Academy of Medicine, Malaysia and is a founding member of hepatitis Support Group ( 2014). Dr Tan Soek Siam is also active internationally. She is a member of the Asian Pacific Association for the Study of the Liver (APASL) ACLF Research Consortium (AARC), member of the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP), and was a member of International Organizing Committee Kyoto Asian Pacific Association of the Study of the Liver Disease Scientific Meeting in 2007.
Dr Tan has been invited as speaker at over 18 international meetings, and had published over 80 papers, 24 full articles in peer review journals and presented more than 50 abstracts locally and internationally. She has been actively involved in both Investigator Initiated Research (IIR) or Industry Sponsored Research ( ISR). She has conducted over 29 ISR , either as Principle Investigator at the Site, National Principle Investigator or as a Co-Investigator.
Dr Tan’s main area of interest is viral hepatitis B and C, decompensated and critically ill chronic liver diseases, acute liver failure , acute-on-chronic liver failure, and liver transplantation.

Dr. David E. Kleiner

Dr. Kleiner received his Ph.D. in 1986 in chemistry and his M.D. in 1988 from the University of Chicago. His graduate work focused on purification of Trichomonal secondary alcohol dehydrogenases, their kinetic characterization, and suicide inactivation. He came to the NIH as a resident in anatomic pathology and after completion of his training, he joined the surgical pathology staff where he has cultivated his interests in the pathology of liver disease, transplantation pathology, and the biochemical mechanisms of tumor cell invasion.

The focus of Dr. Kleiner’s research includes the objective evaluation of pathologic changes following therapy and prediction of disease outcome based on histological parameters. In the absence of an effective therapy or vaccine, it is important to be able to predict not only which patients may expect to benefit from therapy but also which patients are likely to progress more quickly to cirrhosis. Using a multivariate regression model, we have determined clinical and histologic factors that predict short-term progression of fibrosis.

Dr. Kleiner is currently participating in two multicenter clinical networks focused on non-alcoholic fatty liver disease sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases. These two efforts: the NASH Clinical Research Network and the Longitudinal Assessment of Bariatric Surgery will provide both cross-sectional and longitudinal data that will allow evaluation of prognostic factors in fatty liver disease, which may be present 20 to 25% of the U.S. population. Dr. Kleiner is the reference pathologist for the Drug-Induced Liver Injury Network (DILIN). This is an NIDDK-sponsored clinical research network interested in prospective evaluation and investigation of drug-induced liver injury (DILI)is one of the main reasons for removal of drugs from the market. Dr. Kleiner performs blinded reviews for the network and provides information on liver injury classification and detailed histologic descriptive data that is being correlated with individual drugs.

Dr. Loey Mak

Dr Mak received her medical education at The University of Hong Kong. She obtained her qualification of the Membership of the Royal Colleges of Physicians of the United Kingdom in 2013 and the Postgraduate Diploma in Infectious Diseases by The Li Ka Shing Faculty of Medicine of The University of Hong Kong in 2015. She completed her specialty training in Gastroenterology and Hepatology in year 2018 and Advanced Internal Medicine in year 2019 at Queen Mary Hospital.

Dr Mak’s research interests include clinical and translational research of liver diseases, especially in the field of chronic viral hepatitis, fibrosis assessment and non-alcoholic fatty liver disease. She has published more than 100 peer-reviewed articles in reputable journals, with >50 being first-authored/ co-first authored articles. Highlights include 3 first-authored or co-first authored original articles and 1 review article in Journal of Hepatology (impact factor 30.083), and 2 original articles in Hepatology (impact factor 17.298). She is appointed as Honorary Research Fellow of The Centre for Immunology and Infectious Diseases, Blizard Institute, Queen Mary University of London since Jan 2022 to conduct research in the field of HBV immunology.

Dr Mak has received numerous academic awards, including the Dr Kate Cheng Memorial Prize for Postgraduate Diploma in Infectious Diseases, the Best Abstract in Clinical Medicine in the Medical Research Conference organized by The University of Hong Kong in 2017, 2019 and 2020, and 2021, the Young Investigators Award in the Asian Pacific Association of Gastroenterology 3rd Clinical Forum on Inflammatory Bowel Disease in 2018, and the travel award for the 7th Annual Meeting of Asian Organization of Crohn’s & Colitis. She was also awarded the Faculty Knowledge Exchange Award by Li Ka Shing Faculty of Medicine, The University of Hong Kong in 2019. She won the Young Investigator’s Award in the 30th Conference of the Asian Pacific Association for the Study of the Liver, and the Distinguished Research Paper Award by the Hong Kong College of Physicians in year 2020. She is awarded with the Croucher Foundation Fellowship for 2021/2022. Her research paper was awarded with the Faculty Outstanding Research Output Award by The LKS Faculty of Medicine in year 2021 and the Lo Ying Shek Chi Wai Foundation Award for Young Investigator 2020-2021. She was awarded with the Young Investigator Bursary by the European Association for Study of the Liver in year 2021 and 2022.

Dr Mak is the principal investigator and co-investigator for numerous projects funded by externally-competitive grants. She is currently the honorary treasurer for The Hong Kong Association for the Study of Liver Diseases (HKASLD).

Prof. Jonathan Karn

Professor and Chair, Department of Molecular Biology and Microbiology, School of Medicine
Director, Case Center for AIDS Research
Professor, Department of Biochemistry, School of Medicine
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center

HIV persists in the face of highly active antiretroviral therapy (HAART) due to constitutive low-level replication in sites that are poorly accessible to drugs and the development of latent infections in a variety of types including the long-lived memory CD4+ T cell population, macrophages, and microglial cells in the brain – cells that play a critical role in neurologic dysfunction and neurotoxicity. Although HAART has greatly extended survival to patients infected with HIV-1, current therapy has failed to decrease the prevalence of HIV-neurological diseases especially in individuals who abuse drugs.

Dr. Sriram Narayanan

Senior Research Fellow

**Institute of Molecular and Cell Biology, A*STAR**

Singapore
Research focused on innate immune responses in chronic viral infection, specifically on natural killer (NK) cell response and function in chronic HBV.
Research in immunology focused on the biology of IgE producing B cells in human allergic diseases. Also studying the role of other myeloid cells as helpers in regulating class switching to IgE in human atopic diseases.

Dr. Katie Kitrinos

Senior Vice President Preclinical Research and Development at Assembly Biosciences, Inc.

After an extensive career leading virology research and antiviral clinical development programs, I have impacted pre-clinical development and regulatory communications, marketing, commercialization, and 2nd- and 3rd-generation development. I am adept at preparing and delivering high-impact presentations to global audiences, as well as interfacing with clinicians, advisory boards, and key investigators. I have proven to be highly effective in performing hands-on studies, as well as directing scientists conducting research initiatives.

Dr. Prof Peter Revill

Professor Peter Revill is a Senior Medical Scientist at the Victorian Infectious Diseases Reference Laboratory (VIDRL) and a lead of the Global Health cross-cutting discipline at the Doherty Institute. Peter’s work is focused on the molecular virology of hepatitis B virus (HBV), particularly the contribution of different HBV genotypes and variants to the striking differences in natural history, disease progression and treatment response observed globally. Peter holds honorary appointments as Principal Research Fellow in the Departments of Microbiology and Immunology and Pathology at the University of Melbourne, and is an adjunct Associate Professor in the Department of Microbiology at Monash University. Peter is also President of the Australian Centre for Hepatitis Virology (ACHV).

Dr. Mark Anderson

Principal Scientist, Abbott

My work as a microbiologist contributes to our understanding of how diseases impact their hosts, research which brings us closer to treating and preventing deadly infections. I possess expert technical knowledge of life sciences systems and excel at learning new technologies and research topics. As a scientist, I am also skilled at analyzing data, working collaboratively, and communicating my findings to experts and non-experts.

Dr. Gavin Cloherty

Gavin A. Cloherty, Ph.D., is head of Infectious Disease Research and the Pandemic Defense Coalition for Abbott’s diagnostics business. He provides scientific leadership in the area of infectious disease diagnostics by conducting groundbreaking clinical studies on SARS-CoV-2, hepatitis and HIV and developing new diagnostic tests. As one of the top experts in the field, his innovative research is changing the way infectious diseases are being diagnosed to help improve patient outcomes.

Recently, Gavin led efforts to establish the Abbott Pandemic Defense Coalition, a first-of-its-kind, industry-led initiative that has brought together 15 academic and public health organizations located around the world to support early detection and rapid response to pandemic threats. The Coalition is actively hunting, tracking, analyzing and researching numerous pathogens of public health concern in member countries.

Gavin has more than 20 years of experience with Abbott and leads a team of scientists in the study of the viral diversity of HIV and hepatitis. His expertise is sought after globally through his established partnerships with commercial organizations, ministries of health, government agencies and academic institutions, such as the Centers for Disease Control and Prevention (CDC) and National Institutes of Health’s AIDS Clinical Trial Group (ACTG) and Hepatitis B Research Network (HBRN). He has worked with the Republic of Georgia to help eradicate hepatitis C in the country, and is looking to expand these efforts to other regions of the world severely impacted by this disease.

Dr.Klaus Kuhlbusch

MD, MSc with extensive global and local experience in pharmaceutical industry in medical and commercial roles
★ Key indications include oncology/hematology, rheumatology, respiratory, dermatology, transplantation
★ Key roles include local medical advisor, global communication manager, global brand manager, global medical director and head of global medical affairs for biosimilars

Dr. Carey Hwang

Dr Carey Hwang Senior Vice President, Clinical Research, Head of Chronic Infection Vir Biotechnology, Inc.

Carey Hwang serves as Senior Vice President, Clinical Research, for Vir Biotechnology, where he is responsible for the company’s chronic infection clinical development portfolio. Since joining Vir in January 2021, Carey has overseen the development of the Vir lead hepatitis B candidates, VIR-2218 and VIR-3434, as well as its lead HIV vaccine candidate, VIR-1111.

Carey has focused his career on the study and development of treatments for serious infectious diseases, including HIV, hepatitis B and hepatitis C. His industry career began at Bristol Myers Squibb, conducting exploratory clinical and translational research focused on early-phase clinical development of HIV and hepatitis C treatments. He joined Merck & Co. in 2016, where he served as Executive Director and Product Development Lead in Global Clinical Development – Infectious Diseases and led the worldwide development and approval of two treatments for HIV.

He received his bachelor’s degree in molecular biology from Princeton University and his MD and PhD from West Virginia University with a dissertation focused on retroviral recombination. He completed his internal medicine residency and infectious disease fellowship at Vanderbilt University with research focused on the latent reservoir of HIV.

Dr. Scott Balsitis

Senior Director, Hepatitis B Cure Research at Gilead Sciences

Ph.D. team leader with 20 years experience in immunology and development of vaccines and therapeutic small molecules and monoclonal antibodies. Extensive background in pharmaceutical and vaccine development, with emphasis on immunology, virology, and oncology. Reputation for scientific creativity and ability to bring novel drug candidates from concept to clinic. Leadership experience including leading cross-functional project teams, collaborations with external partners, and direct oversight of PhD and non-PhD research staff.

Dr. Wong

Dr Wong is a Consultant specialising in Gastroenterology and Hepatology at the Changi General Hospital, Singapore. He graduated completed his post-graduate residency training in SingHealth, Singapore, and was certified by the Specialist Accreditation Board of Singapore in 2018.

Dr Wong’s research interest is in portal hypertension, liver cirrhosis, viral hepatitis and non-alcoholic fatty liver disease. Dr Wong completed his Master of Clinical Investigator in 2021 and was awarded the nurturing Clinician Scientist Scheme from Medicine ACP, SingHealth the same year on his research in personalizing management for liver cirrhosis patients. His has received awards for his research work and was the recipients for the AASLD abstract awards both in 2022 and 2023.

Dr Wong is also a keen educator and has mentored medical students and residents for their research career. He received the senior educator awards in 2020 and 2022, as well as the Outstanding mentor award by the Singapore Medical Association Charity Fund in 2023. Dr Wong currently holds the appointment as a clinical assistant professor in Duke-NUS Medical School, Singapore.

Prof. Tan Chee Kiat

Senior Consultant
Specialty: Gastroenterology ＆ Hepatology
Sub-specialties: Hepatology, Liver Cancer, Liver Transplantation, Viral Hepatitis

Conditions Treated by this Doctor:
Abnormal Liver Tests, Autoimmune Hepatitis, Fatty Liver Diseases, Hepatitis B, Hepatitis C, Liver Cancer (Hepatocellular Carcinoma), Liver Cirrhosis, Liver Fibrosis, Liver Transplantation, Metabolic Liver Disease, Non-alcoholic Steatohepatitis (NASH), Viral Hepatitis.

Prof Tan Chee Kiat graduated from the Faculty of Medicine, National University of Singapore in 1984. He became a Member of the Royal College of Physicians, United Kingdom [MRCP (UK)] in 1989 and Fellow of the Royal College of Physicians, Edinburgh [(FRCP (Edin)] in 1998. He is also a Fellow of the Academy of Medicine, Singapore in Gastroenterology [FAMS (Gastroenterology)] since 1995. He has trained in Hepatology and Liver Transplantation at the Mayo Clinic, Rochester, Minnesota, USA. He is a fully trained gastroenterologist and besides General Hepatology, his areas of interests are Liver Cancer, Viral Hepatitis and Liver Transplantation. He has set up a nationwide web-based database for hepatocellular carcinoma.

Prof. Jidong Jia

Prof. Jidong Jia is currently Professor of Medicine, Director of Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Professor Jia is the immediate past President of the International Association for the Study of the Liver(IASL), past President of Asian Pacific Association for the Study of the Liver (APASL 2009-2010) and Chinese Society of Hepatology (CSH 2006-2012). Professor Jia also serves as Associate Editor for Hepatology International and served as Associate Editor for Journal of Gastroenterology & Hepatology and Liver International. As a hepatologist, his clinical interests include viral, cholestatic/autoimmune and genetic liver diseases. His research work focuses mainly on cellular and molecular biology of the extracellular matrix of the liver and the pathogenesis and therapeutic study of experimental liver fibrosis. In addition, Dr. Jia has been PI or sub-PI for many clinical trials and also heavily engaged in the teaching of clinical research methodology for residents and fellows in clinical medicine. He has authored or co-authored more than one hundred papers published in national and international journals including Gastroenterology, Gut, Hepatology, and Journal of Hepatology.

Prof. Sven Francque

Prof. Dr. Sven Francque is currently Chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and Full Professor of Medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp in Belgium. He has a longstanding interest and expertise in nonalcoholic fatty liver disease and conducted basic research focusing on the vascular changes in steatosis and their contribution to disease progression. His research unit continues to study pathophysiological mechanisms of NASH. He also conducts clinical research, and his unit is a partner in several research consortia supported by the European Commission. He and his unit participate in most of the clinical trials in the field, and he is a scientific committee member involved in the design of several phase 2 and one of the current phase 3 trials in NAFLD. He is a senior clinical researcher for the Research Fund of the Flemish government. He is board member of several scientific societies and currently also scientific coordinator of the Belgian week of Gastroenterology. Prof. Dr. Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France.

Facebook

Instagram

LinkedIn

Are you an existing user?

Click here to Login

Are you a new user?

Click here to Register